

# the **ADBL** report

Issue #113, March 2020

An Official Accompaniment to the Alberta Drug Benefit List (ADBL) produced by Alberta Blue Cross  
The Expert Committee on Drug Evaluation and Therapeutics (ECDET)

## EXPERT COMMITTEE MEMBERS:

Scott Klarenbach, MD, MSc (Health Econ), FRCPC, (Chair)  
Fiona Clement, PhD, (Vice-Chair)  
Caitlin A. Clarke, BScPhm, PharmD  
Margaret Gray, BSP, FCSHP  
Michael Kolber, BSc, MD, CCFP, MSc  
Naeem Ladhani, BScPharm  
Tony Nickonchuk, BScPharm  
Glen J. Pearson, BScPhm, PharmD, FCSHP, FCCS  
Jeremy Slobodan, BSP  
Donna Woloschuk, BSP, PharmD, M.Ed. FCSHP

## ALBERTA HEALTH LIAISON:

Chad Mitchell, BSc Pharm, MSc

## ADMINISTRATIVE AND SCIENTIFIC SUPPORT:

Julia Chan, BSc (Pharm)  
Amanda Chung, BSc (Pharm)  
Sherry Dieleman, BSc (Pharm), MSc  
Connie Lussier, BSP, MA

## In this issue:

- ***Brief Summary of Drug Review Activities***
- ***Highlights of:***
  - ❖ ***Products Originally Reviewed via the CDR***
  - ❖ ***Interchangeable Drug Products Added***

## ***Brief Summary of Drug Review Activities***

The Expert Committee on Drug Evaluation and Therapeutics met on January 21, 2020. The Committee reviewed Manufacturer submissions for eighteen (18) Drug Products for potential listing, or change in listing, on the *ADBL*. The Committee also considered information for a number of supplementary assessments of the coverage status of two (2) Drug Products.

In addition to Drug Products reviewed by the Expert Committee, nine (9) Drug Products underwent Expedited Review for listing on the *ADBL* effective March 1, 2020.

The following are highlights of recent changes to the *ADBL* and other topics of general interest. A complete list of changes, as well as the full *ADBL* may be accessed at

<https://www.ab.bluecross.ca/dbl/publications.php>

## ***Highlights of Products Originally Reviewed via the Common Drug Review (CDR)***

The following Drug Products were reviewed by CDR and the Expert Committee and added to the *ADBL* effective March 1, 2020:

- **FULPHILA\* 6 mg/0.6 mL injection syringe** (pegfilgrastim) (BGP) via Special Authorization (SA)
- **KALYDECO\* 150 mg tablet** (ivacaftor) (VER) for the indication of cystic fibrosis in patients age 6 years and older who have one of the following mutations in the CFTR gene: G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R, and in patients age 18 years and older with an R117H mutation in the CFTR gene via SA
- **VYZULTA 0.024% ophthalmic solution** (latanoprostene bunod) (VCL)

A complete list of changes, as well as the full *ADBL* may be accessed at <https://www.ab.bluecross.ca/dbl/publications.php>.

\*Please refer to the current *ADBL* for explanations of coverage, including a listing of coverage criteria (where applicable).\*

## ***Highlights of Interchangeable (IC) Drug Products Added***

Addition of the following Entry IC Drug Product to the *ADBL* has resulted in the creation of a New IC Grouping, effective March 1, 2020:

- **ODAN LEVOCARNITINE\* 100 mg/mL oral solution**  
(levocarnitine) (ODN) via SA

*A complete list of changes, as well as the full ADBL may be accessed at <https://www.ab.bluecross.ca/dbl/publications.php>.*

*\*Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).\**